CN119095595A - 用于治疗睡眠紊乱的5-meo-dmt - Google Patents
用于治疗睡眠紊乱的5-meo-dmt Download PDFInfo
- Publication number
- CN119095595A CN119095595A CN202380030914.XA CN202380030914A CN119095595A CN 119095595 A CN119095595 A CN 119095595A CN 202380030914 A CN202380030914 A CN 202380030914A CN 119095595 A CN119095595 A CN 119095595A
- Authority
- CN
- China
- Prior art keywords
- dmt
- meo
- pharmaceutically acceptable
- acceptable salt
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22000083.0 | 2022-03-27 | ||
| EP22000086 | 2022-03-27 | ||
| EP22000086.3 | 2022-03-27 | ||
| EP22000083 | 2022-03-27 | ||
| EP23153995.8 | 2023-01-30 | ||
| EP23153939 | 2023-01-30 | ||
| EP23153995 | 2023-01-30 | ||
| EP23153939.6 | 2023-01-30 | ||
| PCT/EP2023/057827 WO2023186797A1 (en) | 2022-03-27 | 2023-03-27 | 5-meo-dmt for use in the treatment of sleep disturbance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119095595A true CN119095595A (zh) | 2024-12-06 |
Family
ID=86007166
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380030914.XA Pending CN119095595A (zh) | 2022-03-27 | 2023-03-27 | 用于治疗睡眠紊乱的5-meo-dmt |
| CN202380031464.6A Pending CN119053327A (zh) | 2022-03-27 | 2023-03-27 | 用于治疗社交/情感退缩或疏离的5-甲氧基-n,n-二甲基色胺 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380031464.6A Pending CN119053327A (zh) | 2022-03-27 | 2023-03-27 | 用于治疗社交/情感退缩或疏离的5-甲氧基-n,n-二甲基色胺 |
Country Status (9)
| Country | Link |
|---|---|
| US (9) | US20250241893A1 (enExample) |
| EP (7) | EP4499088A1 (enExample) |
| JP (6) | JP2025510912A (enExample) |
| KR (6) | KR20250005183A (enExample) |
| CN (2) | CN119095595A (enExample) |
| AU (6) | AU2023246774A1 (enExample) |
| CA (6) | CA3255348A1 (enExample) |
| IL (6) | IL315899A (enExample) |
| WO (9) | WO2023186820A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3753923A1 (en) | 2019-06-19 | 2020-12-23 | GH Research Limited | Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent |
| EP4155306A1 (en) | 2021-01-15 | 2023-03-29 | Beckley Psytech Limited | Neuroactive ergoline analogue |
| US12534441B2 (en) | 2021-01-15 | 2026-01-27 | Beckley Psytech Limited | Tryptamine analogues |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| GB202306256D0 (en) * | 2023-04-27 | 2023-06-14 | Beckley Psytech Ltd | 5-Methoxy-N,N-Dimethyltryptamine Formulations |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| WO2026078143A1 (en) | 2024-10-09 | 2026-04-16 | GH Research Ireland Limited | Combinations of 5-meo-dmt with antidepressants for treating depression |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19803376C1 (de) | 1998-01-29 | 1999-10-14 | Markus Storz | Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten |
| US20030051728A1 (en) | 2001-06-05 | 2003-03-20 | Lloyd Peter M. | Method and device for delivering a physiologically active compound |
| US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
| US20040234916A1 (en) | 2003-05-21 | 2004-11-25 | Alexza Molecular Delivery Corporation | Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same |
| ES2355983T3 (es) | 2006-08-01 | 2011-04-01 | STOBI GMBH & CO. KG | Balón de válvula para inhaladores . |
| MA50786A (fr) * | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| FI4349407T3 (fi) | 2019-02-22 | 2025-06-02 | Gh Res Ireland Limited | 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon |
| HUE069534T2 (hu) * | 2019-02-22 | 2025-03-28 | Gh Res Ireland Limited | 5-Metoxi-N,N-dimetiltriptamint (5-MeO-DMT) tartalmazó készítmény mentális rendellenességek kezelésében történõ alkalmazásra |
| US12377112B2 (en) * | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| EP3868364A1 (en) * | 2020-02-24 | 2021-08-25 | GH Research Limited | Aerosol comprising 5-methoxy-n,n-dimethyltryptamine |
| WO2021216489A1 (en) * | 2020-04-20 | 2021-10-28 | Lobe Sciences Ltd. | Methods for treating mild traumatic brain injury, post traumatic stress disorder and mild traumatic brain injury |
| BR112022025306A2 (pt) * | 2020-06-12 | 2023-02-28 | Beckley Psytech Ltd | Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina |
| US11406619B2 (en) * | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US20240299353A1 (en) | 2021-03-12 | 2024-09-12 | Alvarius Pharmaceuticals Ltd. | Compositions and methods for treating addictions comprising 5-meo-dmt |
-
2023
- 2023-03-27 IL IL315899A patent/IL315899A/en unknown
- 2023-03-27 CA CA3255348A patent/CA3255348A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057867 patent/WO2023186820A1/en not_active Ceased
- 2023-03-27 EP EP23717412.3A patent/EP4499088A1/en active Pending
- 2023-03-27 CA CA3255340A patent/CA3255340A1/en active Pending
- 2023-03-27 KR KR1020247035762A patent/KR20250005183A/ko active Pending
- 2023-03-27 US US18/850,376 patent/US20250241893A1/en active Pending
- 2023-03-27 AU AU2023246774A patent/AU2023246774A1/en active Pending
- 2023-03-27 KR KR1020247035758A patent/KR20250005181A/ko active Pending
- 2023-03-27 IL IL315902A patent/IL315902A/en unknown
- 2023-03-27 WO PCT/EP2023/057870 patent/WO2023186823A1/en not_active Ceased
- 2023-03-27 EP EP23717035.2A patent/EP4499075A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057857 patent/WO2023186816A1/en not_active Ceased
- 2023-03-27 AU AU2023242291A patent/AU2023242291A1/en active Pending
- 2023-03-27 IL IL315898A patent/IL315898A/en unknown
- 2023-03-27 IL IL315891A patent/IL315891A/en unknown
- 2023-03-27 KR KR1020247035718A patent/KR20250005176A/ko active Pending
- 2023-03-27 EP EP23717036.0A patent/EP4499076A1/en not_active Withdrawn
- 2023-03-27 WO PCT/EP2023/057842 patent/WO2023186806A1/en not_active Ceased
- 2023-03-27 CA CA3255505A patent/CA3255505A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057877 patent/WO2023186830A1/en not_active Ceased
- 2023-03-27 US US18/851,346 patent/US20250241895A1/en active Pending
- 2023-03-27 CA CA3255629A patent/CA3255629A1/en active Pending
- 2023-03-27 KR KR1020247035659A patent/KR20240167879A/ko active Pending
- 2023-03-27 EP EP23717033.7A patent/EP4499073A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057883 patent/WO2023186835A1/en not_active Ceased
- 2023-03-27 JP JP2024557191A patent/JP2025510912A/ja active Pending
- 2023-03-27 JP JP2024557759A patent/JP2025510369A/ja active Pending
- 2023-03-27 AU AU2023246543A patent/AU2023246543A1/en active Pending
- 2023-03-27 EP EP23717042.8A patent/EP4499082A1/en active Pending
- 2023-03-27 US US18/850,383 patent/US20250205256A1/en not_active Abandoned
- 2023-03-27 JP JP2024557755A patent/JP2025511081A/ja active Pending
- 2023-03-27 JP JP2024557758A patent/JP2025510368A/ja active Pending
- 2023-03-27 US US18/850,362 patent/US20250241892A1/en active Pending
- 2023-03-27 CN CN202380030914.XA patent/CN119095595A/zh active Pending
- 2023-03-27 IL IL315897A patent/IL315897A/en unknown
- 2023-03-27 IL IL315896A patent/IL315896A/en unknown
- 2023-03-27 WO PCT/EP2023/057876 patent/WO2023186829A1/en not_active Ceased
- 2023-03-27 CA CA3255343A patent/CA3255343A1/en active Pending
- 2023-03-27 CA CA3255648A patent/CA3255648A1/en active Pending
- 2023-03-27 AU AU2023244452A patent/AU2023244452A1/en active Pending
- 2023-03-27 KR KR1020247035746A patent/KR20250005179A/ko active Pending
- 2023-03-27 JP JP2024557205A patent/JP2025510916A/ja active Pending
- 2023-03-27 US US18/850,348 patent/US20250241891A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057827 patent/WO2023186797A1/en not_active Ceased
- 2023-03-27 EP EP23717031.1A patent/EP4499226A1/en active Pending
- 2023-03-27 EP EP23717043.6A patent/EP4499083A1/en active Pending
- 2023-03-27 US US18/851,343 patent/US20250213532A1/en active Pending
- 2023-03-27 AU AU2023246545A patent/AU2023246545A1/en active Pending
- 2023-03-27 US US18/850,370 patent/US20250205199A1/en active Pending
- 2023-03-27 AU AU2023246679A patent/AU2023246679A1/en active Pending
- 2023-03-27 KR KR1020247035653A patent/KR20250005170A/ko active Pending
- 2023-03-27 WO PCT/EP2023/057873 patent/WO2023186826A1/en not_active Ceased
- 2023-03-27 JP JP2024557204A patent/JP2025512831A/ja active Pending
- 2023-03-27 CN CN202380031464.6A patent/CN119053327A/zh active Pending
- 2023-09-27 US US18/373,903 patent/US20240108601A1/en active Pending
- 2023-09-27 US US18/373,906 patent/US20240108602A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN119095595A (zh) | 用于治疗睡眠紊乱的5-meo-dmt | |
| CN119278036A (zh) | 用于治疗睡眠紊乱的5-MeO-DMT | |
| CN120712084A (zh) | 用于治疗母乳喂养母亲的精神障碍的5-甲氧基-n,n-二甲基色胺 | |
| CN120641095A (zh) | 精神障碍的治疗 | |
| CN118973571A (zh) | 认知功能障碍的治疗 | |
| CN118946352A (zh) | 用于治疗焦虑的5-甲氧基-n,n-二甲基色胺 | |
| CN118973568A (zh) | 精神障碍的治疗 | |
| JP2025510911A (ja) | 精神障害の治療 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |